The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.
The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from other disease indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson's disease therapeutic and intervention development along the pre-clinical and clinical path.
Therapies aiming to address one of the following treatment challenges:
- Protection or restoration of degenerating and/or dysfunctional neurons affected in Parkinson’s
- Alleviation of disabling motor or non-motor symptoms of Parkinson’s not well managed by current treatments
- Reduction of complications and side effects of current Parkinson’s treatments.
Pharmacological interventions as well as biologic, gene therapy, surgical and non-invasive/non-pharmaceutical approaches are appropriate. MJFF is particularly interested in early stage drug discovery efforts for novel PD relevant targets for which there are limited drug campaigns currently active and efforts focused on developing therapeutics that alleviate non-motor symptoms.
Watch our informational webinar on-demand to learn more about our Foundation's funding strategy and opportunities, and the application and review processes. View Now.
Please note we made changes to our publication and indirect costs policies in early 2020. Review the updated Application Guidelines and the new open access publication policy for complete details. Contact email@example.com with questions about the RFA, application process or these policies.